 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 GLOBE NEWSWIRE -- Satsuma Pharmaceuticals, Inc. Nasdaq: STSA, a clinical-stage biopharmaceutical company focused on developing STS101 a dihydroergotamine DHE nasal powder for the acute treatment of migraine, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical development and corporate update. 